IgA tetramerization improves target breadth but not peak potency of functionality of anti-influenza virus broadly neutralizing antibody.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
01 2019
Historique:
received: 15 05 2018
accepted: 22 10 2018
entrez: 4 1 2019
pubmed: 4 1 2019
medline: 27 3 2019
Statut: epublish

Résumé

Mucosal immunoglobulins comprise mainly secretory IgA antibodies (SIgAs), which are the major contributor to pathogen-specific immune responses in mucosal tissues. These SIgAs are highly heterogeneous in terms of their quaternary structure. A recent report shows that the polymerization status of SIgA defines their functionality in the human upper respiratory mucosa. Higher order polymerization of SIgA (i.e., tetramers) leads to a marked increase in neutralizing activity against influenza viruses. However, the precise molecular mechanisms underlying the effects of SIgA polymerization remain elusive. Here, we developed a method for generating recombinant tetrameric monoclonal SIgAs. We then compared the anti-viral activities of these tetrameric SIgAs, which possessed variable regions identical to that of a broadly neutralizing anti-influenza antibody F045-092 against influenza A viruses, with that of monomeric IgG or IgA. The tetrameric SIgA showed anti-viral inhibitory activity superior to that of other forms only when the antibody exhibits low-affinity binding to the target. By contrast, SIgA tetramerization did not substantially modify anti-viral activity against targets with high-affinity binding. Taken together, the data suggest that tetramerization of SIgA improved target breadth, but not peak potency of antiviral functions of the broadly neutralizing anti-influenza antibody. This phenomenon presumably represents one of the mechanisms by which SIgAs present in human respiratory mucosa prevent infection by antigen-drifted influenza viruses. Understanding the mechanisms involved in cross neutralization of viruses by SIgAs might facilitate the development of vaccine strategies against viral infection of mucosal tissues.

Identifiants

pubmed: 30605488
doi: 10.1371/journal.ppat.1007427
pii: PPATHOGENS-D-18-00987
pmc: PMC6317788
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0
Antiviral Agents 0
Hemagglutinin Glycoproteins, Influenza Virus 0
Immunoglobulin A 0
Immunoglobulin A, Secretory 0
Influenza Vaccines 0
Recombinant Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1007427

Déclaration de conflit d'intérêts

National Institute of Infectious Diseases and Nippi, Inc. have filed patents regarding construction and use of tetrameric SIgA (application no. PCT/JP2015/070742). SS, TS, AA, YT, TU, KOG and HH are named as inventors on the application. YT, TU, and KOG are employees of Nippi, Inc.

Références

Methods Enzymol. 1985;116:37-75
pubmed: 3911017
Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6364-8
pubmed: 9177223
Appl Microbiol. 1969 Nov;18(5):824-33
pubmed: 4984203
Med Microbiol Immunol. 1975 Dec 30;162(1):9-14
pubmed: 1214709
J Biol Chem. 1999 Nov 19;274(47):33771-7
pubmed: 10559270
Emerg Microbes Infect. 2017 Dec 6;6(12):e110
pubmed: 29209053
Mol Immunol. 1997 Mar;34(4):323-31
pubmed: 9244345
J Immunol. 2010 Apr 1;184(7):3648-55
pubmed: 20208001
Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):3029-34
pubmed: 10077631
Nat Rev Immunol. 2012 Dec;12(12):821-32
pubmed: 23103985
J Virol. 2003 Apr;77(7):4095-103
pubmed: 12634368
J Virol. 2011 Nov;85(21):11048-57
pubmed: 21865387
Vaccine. 2017 Sep 18;35(39):5297-5302
pubmed: 28780981
AIDS. 2013 Jun 1;27(9):F13-20
pubmed: 23775002
mBio. 2017 Mar 21;8(2):
pubmed: 28325769
J Infect Dis. 2011 Dec 15;204(12):1879-85
pubmed: 21998477
mSphere. 2017 Dec 13;2(6):
pubmed: 29242836
J Immunol. 1996 Jul 1;157(1):156-9
pubmed: 8683109
Science. 2004 Mar 19;303(5665):1866-70
pubmed: 14764887
J Clin Microbiol. 1985 Aug;22(2):259-64
pubmed: 4031039
J Immunol Methods. 2015 Jul;422:102-10
pubmed: 25910833
Mucosal Immunol. 2017 Jan;10(1):228-237
pubmed: 27072605
Mucosal Immunol. 2009 Sep;2(5):412-26
pubmed: 19587640
PLoS Pathog. 2010 Mar 12;6(3):e1000801
pubmed: 20300659
Antiviral Res. 2014 Jul;107:76-83
pubmed: 24797696
Mucosal Immunol. 2008 Jan;1(1):11-22
pubmed: 19079156
J Exp Med. 1965 Jan 1;121:101-24
pubmed: 14253478
J Virol. 2004 Oct;78(20):11007-15
pubmed: 15452221
J Immunol. 1973 Dec;111(6):1653-60
pubmed: 4201552
J Immunol Methods. 2008 Jan 1;329(1-2):112-24
pubmed: 17996249
J Immunol. 2005 Nov 15;175(10):6694-701
pubmed: 16272325
Hum Vaccin Immunother. 2018 Jun 3;14(6):1351-1361
pubmed: 29425074
Viral Immunol. 2012 Oct;25(5):433-9
pubmed: 22985289
Mucosal Immunol. 2011 Nov;4(6):590-7
pubmed: 21937984
Nat Commun. 2014 Apr 10;5:3614
pubmed: 24717798
Cell Rep. 2018 Apr 3;23(1):90-99
pubmed: 29617676
PLoS One. 2014 Jan 17;9(1):e85582
pubmed: 24465606
Influenza Other Respir Viruses. 2016 Nov;10(6):518-524
pubmed: 27406695
Blood. 2012 Nov 29;120(23):4571-82
pubmed: 23065154
Infect Immun. 1985 Aug;49(2):459-62
pubmed: 2410367
Proc Natl Acad Sci U S A. 2015 Jun 23;112(25):7809-14
pubmed: 26056267
Vaccine. 2017 Sep 25;35(40):5388-5395
pubmed: 28866292
Mucosal Immunol. 2017 May;10(3):814-826
pubmed: 27966557
Hum Vaccin Immunother. 2013 Sep;9(9):1962-70
pubmed: 23896606

Auteurs

Shinji Saito (S)

Department of Pathology, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan.
Influenza Virus Research Center, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan.

Kaori Sano (K)

Department of Pathology, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan.
Division of Infectious Diseases Pathology, Department of Global Infectious Diseases, Tohoku Graduate School of Medicine, Sendai, Miyagi, Japan.

Tadaki Suzuki (T)

Department of Pathology, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan.

Akira Ainai (A)

Department of Pathology, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan.

Yuki Taga (Y)

Nippi Research Institute of Biomatrix, Toride, Ibaraki, Japan.

Tomonori Ueno (T)

Nippi Research Institute of Biomatrix, Toride, Ibaraki, Japan.

Koshiro Tabata (K)

Department of Pathology, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan.

Kumpei Saito (K)

Department of Pathology, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan.

Yuji Wada (Y)

Department of Pathology, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan.

Yuki Ohara (Y)

Department of Pathology, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan.

Haruko Takeyama (H)

Department of Life Science and Medical Bioscience, Waseda University, Shinjuku, Tokyo, Japan.

Takato Odagiri (T)

Influenza Virus Research Center, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan.

Tsutomu Kageyama (T)

Influenza Virus Research Center, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan.

Kiyoko Ogawa-Goto (K)

Nippi Research Institute of Biomatrix, Toride, Ibaraki, Japan.

Pretty Multihartina (P)

National Institute of Health Research and Development, Ministry of Health RI, Jakarta, Indonesia.

Vivi Setiawaty (V)

National Institute of Health Research and Development, Ministry of Health RI, Jakarta, Indonesia.

Krisna Nur Andriana Pangesti (KNA)

National Institute of Health Research and Development, Ministry of Health RI, Jakarta, Indonesia.

Hideki Hasegawa (H)

Department of Pathology, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan.
Division of Infectious Diseases Pathology, Department of Global Infectious Diseases, Tohoku Graduate School of Medicine, Sendai, Miyagi, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH